Literature DB >> 9230747

The value of routine microbial investigation in ventilator-associated pneumonia.

J Rello1, M Gallego, D Mariscal, R Soñora, J Valles.   

Abstract

The use of microbiologic investigations in routine clinical practice, their value in guiding antibiotic prescription, and their influence on outcome were prospectively studied in 113 consecutive adults who developed ventilator-associated pneumonia (VAP). Blood cultures were performed in 78.7% of cases, protected specimen brushing in 95.5%, and bronchoalveolar lavage in only 45.1%. No causative agent was identified in 13 episodes (11.5%), and results of microbial tests directed a change in therapy in 43 (38.0%). Bronchoscopic results revealed inadequate initial selection of antibiotic therapy in 27 cases (23.9%) and led to a change in antibiotic treatment. Inadequate initial selection was still associated with a significantly greater increase in related mortality than adequate initial therapy (37.0% versus 15.4%, p < 0.05), although the change in therapy permitted clinical resolution in 17 (62.9%) of these 27 episodes, and 10 patients were discharged alive. Bronchoscopic results also permitted the reduction of the antibiotic spectrum in seven episodes (6.1%). This study suggests that in patients with VAP, bronchoscopic results are frequently associated with changes in antibiotic therapy. Nevertheless, our findings also emphasize the critical importance of an appropriate early antibiotic therapy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9230747     DOI: 10.1164/ajrccm.156.1.9607030

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  78 in total

Review 1.  Diagnosis of pneumonia and monitoring of infection eradication.

Authors:  M Ruiz; C Arosio; P Salman; T T Bauer; A Torres
Journal:  Drugs       Date:  2000-12       Impact factor: 9.546

2.  Optimal use of antibiotics for intubation-associated pneumonia.

Authors:  J Rello; E Diaz
Journal:  Intensive Care Med       Date:  2001-02       Impact factor: 17.440

Review 3.  Appropriate antibiotic therapy for ventilator-associated pneumonia and sepsis: a necessity, not an issue for debate.

Authors:  Marin H Kolleff
Journal:  Intensive Care Med       Date:  2003-02       Impact factor: 17.440

4.  Acinetobacter baumannii: a threat for the ICU?

Authors:  Jordi Rello; Emili Diaz
Journal:  Intensive Care Med       Date:  2003-02-13       Impact factor: 17.440

5.  Outcome of postoperative pneumonia in the Eole study.

Authors:  Hervé Dupont; Philippe Montravers; Rémy Gauzit; Benoît Veber; Jean-Louis Pouriat; Claude Martin
Journal:  Intensive Care Med       Date:  2003-01-14       Impact factor: 17.440

6.  Pulmonary Infections in Ventilated Patients: Diagnostic and Therapeutic Options.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-06       Impact factor: 3.725

7.  Both early-onset and late-onset ventilator-associated pneumonia are caused mainly by potentially multiresistant bacteria.

Authors:  Elpis Giantsou; Nikolaos Liratzopoulos; Eleni Efraimidou; Maria Panopoulou; Eleonora Alepopoulou; Sofia Kartali-Ktenidou; George I Minopoulos; Spyros Zakynthinos; Konstantinos I Manolas
Journal:  Intensive Care Med       Date:  2005-09-07       Impact factor: 17.440

8.  Direct examination and cultures of bronchoalveolar lavage in pneumonia diagnosis: a comparative experimental study.

Authors:  Nilton Brandão da Silva; Lucas Martins; Frederico Martins; José Anflor; Tiago Tonietto; Cristiano Koefender; Paulo G Cardoso; José Moreira
Journal:  Intensive Care Med       Date:  2007-08-03       Impact factor: 17.440

Review 9.  Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness.

Authors:  Rina Mehrotra; Raffaele De Gaudio; Mark Palazzo
Journal:  Intensive Care Med       Date:  2004-11-05       Impact factor: 17.440

10.  Outcome in bacteremia associated with nosocomial pneumonia and the impact of pathogen prediction by tracheal surveillance cultures.

Authors:  Pieter Depuydt; Dominique Benoit; Dirk Vogelaers; Geert Claeys; Gerda Verschraegen; Koenraad Vandewoude; Johan Decruyenaere; Stijn Blot
Journal:  Intensive Care Med       Date:  2006-09-16       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.